PATENT



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Mustapha Haddach et al.

Application No.

10/785,386

:

Filed

February 23, 2004

For

CRF RECEPTOR ANTAGONISTS AND METHODS

RELATING THERETO

Art Unit

: 1614

Docket No.

690068.459C4

Date

: July 15, 2004

Mail Stop Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Form PTO-1449. This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 10/027,789, filed December 20, 2001, now U.S. Patent 6,723,721, which is a continuation of prior Application No. 09/439,841, filed November 12, 1999, now U.S. Patent 6,348,466, which is a continuation-in-part of prior Application No. 09/400,744, filed September 21, 1999, now abandoned, which is a continuation-in-part of prior Application No. 09/190,958, filed November 12, 1998, now abandoned. The references listed on the attached Forms PTO-1449 were submitted to and/or cited by the Patent and Trademark Office in these prior applications and, therefore, are not required to be provided in this application. If the Examiner wishes, copies will be provided upon request. As to any reference made of record on the attached form PTO-1449, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the

Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

Karl R. Hermanns

Registration No. 33,507

Enclosures:

Form PTO-1449

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

1 ax. (200) 002-00.

496833

FORM PTO-1449 (REV.7-80)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO. 690068.459C4

APPLICATION NO. 10/785,386

APPLICANTS

Mustapha Haddach et al.

FILING DATE

GROUP ART UNIT

February 23, 2004

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,605,642	08/12/86	Rivier et al.	514	12	
	AB	4,904,658	02/27/90	Tseng et al.	514	233.2	
ļ	AC	5,063,245	11/05/91	Abreu et al.	514	404	
	AD	5,464,847	11/07/95	Courtemanche et al.	514	342	
	AE	5,880,135	03/09/99	Gully et al.	514	307	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AF	WO 94/13643	06/23/94	WIPO		
· .	AG	WO 94/13644	06/23/94	WIPO		
	АН	WO 94/13661	06/23/94	WIPO		
	AI	WO 94/13676	06/23/94	WIPO		
	AJ	WO 94/13677	06/23/94	WIPO		
	AK	WO 95/10506	04/20/95	WIPO		
	AL	WO 95/33750	12/14/95	WIPO		
	AM	WO 95/34563	12/21/95	WIPO		
	AN	WO 96/35689	11/14/96	WIPO		
	AO	WO 97/00868	01/09/97	WIPO		Х

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

АР	De Souza et al., "Heterogeneity of Corticotropin Releasing Factor Receptors: Multiple Targets for the Treatment of CNS and Inflammatory Disorders," <i>Annual Reports in Medicinal Chemistry</i> 30:21-30, 1995.
AQ	McCarthy et al., "Recent Progress in Corticotropin-Releasing Factor Receptor Agents," Annual Reports in Medicinal Chemistry 34:11-20, 1999.
AR	Rivier et al., "Synthetic Competitive Antagonists of Corticotropin-Releasing Factor: Effect on ACTH Secretion in the Rat," <i>Science 224</i> : 889-891, 1984.

EXAMINER

DATE CONSIDERED

^{*} EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

EXPRESS MAIL NO. EV335393221US

Sheet $\underline{2}$ of $\underline{2}$

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO.

APPLICATION NO.

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				690068.459C4 10/785,386					
				APPLICANTS Mustapha Haddach et al.					
				FILING DATE GROUP ART UNIT February 23, 2004 1614					
			U.S. I	PATENT I	DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS SUBCLASS		FILING DATE IF APPROPRIATI	
E	за								
E	3В								
E	зс								
			FOREIG	N PATEN	T DOCUMENTS				
		DOCUMENT NUMBER	DATE		COUNTRY			TRANS	LATION
В	3D	WO 97/35539	10/02/97	WIPO					
В	3E	WO 97/35580	10/02/97	WIPO					
В	3F	WO 97/35846	10/02/97	WIPO					
В	3G	WO 97/44038	11/27/97	WIPO					
В	зн	WO 98/03510	01/29/98	WIPO					
В	31	WO 98/05661	02/12/98	WIPO					
В	3J	WO 98/08846	03/05/98	WIPO					
В	зк	WO 98/08847	03/05/98	WIPO					
В	3L	WO 98/11075	03/19/98	WIPO					
В	вм	WO 98/15543	04/16/98	WIPO			•		X
В	BN	WO 98/21200	05/22/98	WIPO					
В	80	WO 98/29413	07/09/98	WIPO					
		OTHER	PRIOR AR	T (Including	Author, Title, Date, Pertinent Po	iges, Etc.)			
В	3P								
В	IQ								
В	R								
XAMINER		•			DATE CONSIDERED				

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).